A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events

Andres M. Kanner; Joanne Wuu; Edward Faught; William O. Tatum IV; Aaron Fix; Jacqueline A. French; Blaise B.E. Bourgeois; Lawrence Brown; Robert Burgerman; Giuseppe Erba; Edward Faught; Cynthia Harden; Mercedes Jacobson; Joyce Liporace; Georgia Montouris; George Morris; Michael Privitera; William Rosenfield; David Vossler

doi:10.1016/j.yebeh.2003.07.007

A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events

Andres M. Kanner, Joanne Wuu, Edward Faught, William O. Tatum IV, Aaron Fix, Jacqueline A. French, Blaise B.E. Bourgeois, Lawrence Brown, Robert Burgerman, Giuseppe Erba, Edward Faught, Cynthia Harden, Mercedes Jacobson, Joyce Liporace, Georgia Montouris, George Morris, Michael Privitera, William Rosenfield, David Vossler

Research output: Contribution to journal › Article › peer-review

75 Scopus citations

Abstract

Objectives. Topiramate (TPM) is a new antiepileptic drug (AED) that has been found to be associated with a high prevalence of cognitive adverse events (CAEs). The prevalence of psychiatric adverse events (PAEs) has yet to be established. The purpose of this study was to determine the prevalence of PAEs related to TPM when used in polytherapy regimens in a large cohort of adult patients with epilepsy, to identify any association between the occurrences of CAEs and PAEs and to identify predictors of PAEs and CAEs. Methods. Investigators from 16 epilepsy centers (PADS group) prospectively obtained postmarketing safety and efficacy data on 596 patients aged 16 years and older. All data were recorded on standardized data retrieval forms, completed at the initial visit, while follow-up data were obtained every 6 months or at the time of discontinuation. Results. PAEs were identified in 75 (12.6%) patients: 30 (5%) experienced symptoms of depression and 34 (5.7%) of aggressive behavior and irritability, while 9 patients experienced symptoms of psychosis (1.5%). CAEs were reported by 247 (41.5%) patients. There was a significant association between the occurrences of CAEs and PAEs. A past psychiatric history was a predictor of CAEs, while older age and past psychiatric history were predictors of PAEs. Conclusions. The use of TPM in polytherapy regimens can cause PAEs and CAEs and their occurrence is significantly correlated. Patients with a past psychiatric history may be at a higher risk for experiencing PAEs and CAEs.

Original language	English (US)
Pages (from-to)	548-552
Number of pages	5
Journal	Epilepsy and Behavior
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/j.yebeh.2003.07.007
State	Published - Oct 2003
Externally published	Yes

Keywords

Aggressive behavior
Antiepileptic drugs
Depression
Epilepsy
Memory problems
Polytherapy
Psychosis
Slow thinking

ASJC Scopus subject areas

Clinical Neurology
Behavioral Neuroscience
Neurology

Access to Document

10.1016/j.yebeh.2003.07.007

Fingerprint Dive into the research topics of 'A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events'. Together they form a unique fingerprint.

Cite this

Kanner, A. M., Wuu, J., Faught, E., Tatum IV, W. O., Fix, A., French, J. A., Bourgeois, B. B. E., Brown, L., Burgerman, R., Erba, G., Faught, E., Harden, C., Jacobson, M., Liporace, J., Montouris, G., Morris, G., Privitera, M., Rosenfield, W., & Vossler, D. (2003). A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy and Behavior, 4(5), 548-552. https://doi.org/10.1016/j.yebeh.2003.07.007

A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. / Kanner, Andres M.; Wuu, Joanne; Faught, Edward; Tatum IV, William O.; Fix, Aaron; French, Jacqueline A.; Bourgeois, Blaise B.E.; Brown, Lawrence; Burgerman, Robert; Erba, Giuseppe; Faught, Edward; Harden, Cynthia; Jacobson, Mercedes; Liporace, Joyce; Montouris, Georgia; Morris, George; Privitera, Michael; Rosenfield, William; Vossler, David.

In: Epilepsy and Behavior, Vol. 4, No. 5, 10.2003, p. 548-552.

Research output: Contribution to journal › Article › peer-review

Kanner, AM , Wuu, J, Faught, E, Tatum IV, WO, Fix, A, French, JA, Bourgeois, BBE, Brown, L, Burgerman, R, Erba, G, Faught, E, Harden, C, Jacobson, M, Liporace, J, Montouris, G, Morris, G, Privitera, M, Rosenfield, W & Vossler, D 2003, 'A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events', Epilepsy and Behavior, vol. 4, no. 5, pp. 548-552. https://doi.org/10.1016/j.yebeh.2003.07.007

Kanner, Andres M. ; Wuu, Joanne ; Faught, Edward ; Tatum IV, William O. ; Fix, Aaron ; French, Jacqueline A. ; Bourgeois, Blaise B.E. ; Brown, Lawrence ; Burgerman, Robert ; Erba, Giuseppe ; Faught, Edward ; Harden, Cynthia ; Jacobson, Mercedes ; Liporace, Joyce ; Montouris, Georgia ; Morris, George ; Privitera, Michael ; Rosenfield, William ; Vossler, David. / A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. In: Epilepsy and Behavior. 2003 ; Vol. 4, No. 5. pp. 548-552.

@article{fdff96c4a6f44d1995ba9b548288a54e,

title = "A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events",

abstract = "Objectives. Topiramate (TPM) is a new antiepileptic drug (AED) that has been found to be associated with a high prevalence of cognitive adverse events (CAEs). The prevalence of psychiatric adverse events (PAEs) has yet to be established. The purpose of this study was to determine the prevalence of PAEs related to TPM when used in polytherapy regimens in a large cohort of adult patients with epilepsy, to identify any association between the occurrences of CAEs and PAEs and to identify predictors of PAEs and CAEs. Methods. Investigators from 16 epilepsy centers (PADS group) prospectively obtained postmarketing safety and efficacy data on 596 patients aged 16 years and older. All data were recorded on standardized data retrieval forms, completed at the initial visit, while follow-up data were obtained every 6 months or at the time of discontinuation. Results. PAEs were identified in 75 (12.6%) patients: 30 (5%) experienced symptoms of depression and 34 (5.7%) of aggressive behavior and irritability, while 9 patients experienced symptoms of psychosis (1.5%). CAEs were reported by 247 (41.5%) patients. There was a significant association between the occurrences of CAEs and PAEs. A past psychiatric history was a predictor of CAEs, while older age and past psychiatric history were predictors of PAEs. Conclusions. The use of TPM in polytherapy regimens can cause PAEs and CAEs and their occurrence is significantly correlated. Patients with a past psychiatric history may be at a higher risk for experiencing PAEs and CAEs.",

keywords = "Aggressive behavior, Antiepileptic drugs, Depression, Epilepsy, Memory problems, Polytherapy, Psychosis, Slow thinking",

author = "Kanner, {Andres M.} and Joanne Wuu and Edward Faught and {Tatum IV}, {William O.} and Aaron Fix and French, {Jacqueline A.} and Bourgeois, {Blaise B.E.} and Lawrence Brown and Robert Burgerman and Giuseppe Erba and Edward Faught and Cynthia Harden and Mercedes Jacobson and Joyce Liporace and Georgia Montouris and George Morris and Michael Privitera and William Rosenfield and David Vossler",

year = "2003",

month = oct,

doi = "10.1016/j.yebeh.2003.07.007",

language = "English (US)",

volume = "4",

pages = "548--552",

journal = "Epilepsy and Behavior",

issn = "1525-5050",

publisher = "Academic Press Inc.",

number = "5",

}

TY - JOUR

T1 - A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events

AU - Kanner, Andres M.

AU - Wuu, Joanne

AU - Faught, Edward

AU - Tatum IV, William O.

AU - Fix, Aaron

AU - French, Jacqueline A.

AU - Bourgeois, Blaise B.E.

AU - Brown, Lawrence

AU - Burgerman, Robert

AU - Erba, Giuseppe

AU - Faught, Edward

AU - Harden, Cynthia

AU - Jacobson, Mercedes

AU - Liporace, Joyce

AU - Montouris, Georgia

AU - Morris, George

AU - Privitera, Michael

AU - Rosenfield, William

AU - Vossler, David

PY - 2003/10

Y1 - 2003/10

N2 - Objectives. Topiramate (TPM) is a new antiepileptic drug (AED) that has been found to be associated with a high prevalence of cognitive adverse events (CAEs). The prevalence of psychiatric adverse events (PAEs) has yet to be established. The purpose of this study was to determine the prevalence of PAEs related to TPM when used in polytherapy regimens in a large cohort of adult patients with epilepsy, to identify any association between the occurrences of CAEs and PAEs and to identify predictors of PAEs and CAEs. Methods. Investigators from 16 epilepsy centers (PADS group) prospectively obtained postmarketing safety and efficacy data on 596 patients aged 16 years and older. All data were recorded on standardized data retrieval forms, completed at the initial visit, while follow-up data were obtained every 6 months or at the time of discontinuation. Results. PAEs were identified in 75 (12.6%) patients: 30 (5%) experienced symptoms of depression and 34 (5.7%) of aggressive behavior and irritability, while 9 patients experienced symptoms of psychosis (1.5%). CAEs were reported by 247 (41.5%) patients. There was a significant association between the occurrences of CAEs and PAEs. A past psychiatric history was a predictor of CAEs, while older age and past psychiatric history were predictors of PAEs. Conclusions. The use of TPM in polytherapy regimens can cause PAEs and CAEs and their occurrence is significantly correlated. Patients with a past psychiatric history may be at a higher risk for experiencing PAEs and CAEs.

AB - Objectives. Topiramate (TPM) is a new antiepileptic drug (AED) that has been found to be associated with a high prevalence of cognitive adverse events (CAEs). The prevalence of psychiatric adverse events (PAEs) has yet to be established. The purpose of this study was to determine the prevalence of PAEs related to TPM when used in polytherapy regimens in a large cohort of adult patients with epilepsy, to identify any association between the occurrences of CAEs and PAEs and to identify predictors of PAEs and CAEs. Methods. Investigators from 16 epilepsy centers (PADS group) prospectively obtained postmarketing safety and efficacy data on 596 patients aged 16 years and older. All data were recorded on standardized data retrieval forms, completed at the initial visit, while follow-up data were obtained every 6 months or at the time of discontinuation. Results. PAEs were identified in 75 (12.6%) patients: 30 (5%) experienced symptoms of depression and 34 (5.7%) of aggressive behavior and irritability, while 9 patients experienced symptoms of psychosis (1.5%). CAEs were reported by 247 (41.5%) patients. There was a significant association between the occurrences of CAEs and PAEs. A past psychiatric history was a predictor of CAEs, while older age and past psychiatric history were predictors of PAEs. Conclusions. The use of TPM in polytherapy regimens can cause PAEs and CAEs and their occurrence is significantly correlated. Patients with a past psychiatric history may be at a higher risk for experiencing PAEs and CAEs.

KW - Aggressive behavior

KW - Antiepileptic drugs

KW - Depression

KW - Epilepsy

KW - Memory problems

KW - Polytherapy

KW - Psychosis

KW - Slow thinking

UR - http://www.scopus.com/inward/record.url?scp=10744230559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744230559&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2003.07.007

DO - 10.1016/j.yebeh.2003.07.007

M3 - Article

C2 - 14527497

AN - SCOPUS:10744230559

VL - 4

SP - 548

EP - 552

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 5

ER -